A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells
- 13 February 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (7), 505-509
- https://doi.org/10.1182/blood.2019001859
Abstract
Unintentional transduction of B-cell acute lymphoblastic leukemia blasts during CART19 manufacturing can lead to CAR19(+) leukemic cells (CARB19) that are resistant to CART19 killing. We developed an anti-CAR19 idiotype chimeric antigen receptor (alpha CAR19) to specifically recognize CAR19(+) cells. aCAR19 CAR T cells efficiently lysed CARB19 cells in vitro and in a primary leukemia-derived xenograft model. We further showed that alpha CAR19-CART cells could be used as an "antidote" to deplete CART19 cells to reduce long-term side effects, such as B-cell aplasia.This publication has 22 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cellsBlood, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical TrialsPLOS ONE, 2013
- Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaBlood, 2013
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyThe New England Journal of Medicine, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004